B Cell Lymphoma

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

SynKIR-310 for Relapsed/Refractory B-NHL

Long-Term Follow-up Study

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Exploratory Study on the Efficacy of Zebutinib as Maintenance Therapy Following CAR-T Cell Therapy in Patients With Non-Hodgkin B-Cell Lymphoma

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)